|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Results:</b> CL-PEG-pSL showed rapid endo/lysosome-escape abilities in the cancer cells and higher tumor accumulation in MIA PaCa-2 xenograft model in contrast to PEG-pSL.
|
31355712 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>In vivo</i> tumor imaging demonstrated that the targeting recognition of MIA PaCa-2 tumor cells in mice could be visualized using Cy5-labeled aptamer M17.
|
31289496 |
2019 |
|
Malignant transformation
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Malignant transformation of melanocytes to melanoma cells closely parallels activation of melanoma inhibitory activity (MIA) expression.
|
12665595 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumors of MIA PaCa-2 cells transfected with OGFr cDNA (OGFr-1) had 3.3 times more OGFr than empty vector (EV) neoplasias, and 4.3 times more OGFr than tumors from wild-type (WT) mice.
|
18636152 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor cell spheres developed in PANC-1 and MIA-Paca-2 in serum-free medium.
|
21813394 |
2011 |
|
Multiple gastrointestinal atresias (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
Hereditary multiple intestinal atresia (HMIA) with severe combined immunodeficiency (SCID): a case report of two siblings and review of the literature on MIA, HMIA and HMIA with immunodeficiency over the last 50 years.
|
22715199 |
2011 |
|
Malnutrition
|
0.010 |
Biomarker
|
disease |
BEFREE |
Malnutrition-Inflammation-Atherosclerosis (MIA) factors significantly and independently affect life prognosis of hemodialysis (HD) patients.
|
28038804 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor growth in the MIA Paca2 xenograft model was inhibited by TGZ administration, while mouse body weights in the treated group were not different from those of the vehicle administration group.
|
28673319 |
2017 |
|
Trichohepatoenteric Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Tricho-hepato-enteric syndrome (SD/THE) and Multiple intestinal atresia with combined immune deficiency (MIA-CID) are autosomal recessive disorders that present immunological and gastrointestinal features.
|
29174094 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma inhibitory activity (MIA) is one such melanoma-specific candidate gene.
|
10576666 |
1999 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma inhibitory activity (MIA) protein is a clinically valuable marker in patients with malignant melanoma, as enhanced values diagnose metastatic melanoma stages III and IV.
|
11157741 |
2001 |
|
Pancreatic Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
MIA-PaCa2-GFP and BxPC-3-GFP tumor fragments were transplanted by surgical orthotopic implantation (SOI) to the nude mouse pancreas for fluorescence visualization of the chronology of pancreatic tumor growth and metastatic targeting.
|
11315094 |
2000 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MIA-PaCa-2 human pancreatic cancer cells were treated in vitro with the 26S-proteasome inhibitor PS-341.
|
11516199 |
2001 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
MIA-PaCa-2 human pancreatic cancer cells were treated in vitro with the 26S-proteasome inhibitor PS-341.
|
11516199 |
2001 |
|
Adenocarcinoma
|
0.070 |
Biomarker
|
group |
BEFREE |
MIA PaCa-2 pancreatic head exocrine adenocarcinoma cells (mutant p53) were treated by mock infection or adenoviruses expressing beta-galactosidase or E2F-1 (Ad-E2F-1) alone or in combination with sublethal concentrations of each chemotherapeutic drug.
|
12065845 |
2002 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Melanoma inhibitory activity, secreted by melanoma cells, is known to inhibit tumour cell attachment to the extracellular matrix enhancing their invasive potential.
|
15057037 |
2004 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma.
|
15118759 |
2004 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Melanoma inhibitory activity (MIA) is an 11 kD protein secreted by malignant melanomas.
|
15386421 |
2005 |
|
Malignant neoplasm of stomach
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
MIA and GW112 were overexpressed in 10 (25%) and 22 (55%) of 40 GC samples, and the overexpression of these two genes was associated with tumor stage, respectively.
|
16210872 |
2005 |
|
Stomach Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MIA and GW112 were overexpressed in 10 (25%) and 22 (55%) of 40 GC samples, and the overexpression of these two genes was associated with tumor stage, respectively.
|
16210872 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MIA and GW112 were overexpressed in 10 (25%) and 22 (55%) of 40 GC samples, and the overexpression of these two genes was associated with tumor stage, respectively.
|
16210872 |
2005 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Melanoma inhibitory activity (MIA) has been identified as a small protein secreted from malignant melanoma cells, which strongly enhances melanoma cell migration and invasion.
|
19200257 |
2009 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma inhibitory activity (MIA) has been shown to play an essential role in the progression of malignant melanoma and to influence melanoma-associated molecules and pathways in the early tumor formation steps.
|
21642354 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MIA PaCa-2 cells with endogenously overexpressed miR-100 were transplanted into null mice to examine tumor growth in vivo.
|
25344675 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MIA-690 inhibited the proliferation of A-375 cells in a dose-dependent manner (33% at 10 μM, and 19.2% at 5 μM, P < 0 .05 vs. control), and suppressed the growth of xenografted tumors by 70.45% (P < 0.05).
|
25486366 |
2014 |